Cereno Scientific strengthens patent protection for CS1 with first granted patent in the third patent family
Cereno Scientific (XSAT: CRNO B) today announced that intellectual property rights (IPR) for drug candidate CS1’s third patent family has been granted in Russia. This is the first patent grant in the third patent family, adding to Cereno’s extensive patent protection across nearly all global key markets.“It is great to see our continuous work in securing IPR for our assets paying off with further strengthening of the patent protection for CS1 in the Russian market.” says Sten R. Sörensen, CEO at Cereno Scientific. Jonas Faijerson Säljö, Chief Intellectual Property Officer at Cereno